ACTR-68. CONCORDANCE OF EGFR AND MGMT ANALYSES BETWEEN LOCAL AND CENTRAL LABORATORIES: IMPLICATIONS FOR CLINICAL TRIAL DESIGN AND PRECISION MEDICINE FOR DEPATUXIZUMAB-MAFODOTIN (ABT-414) IN GLIOBLASTOMA (GBM)

BACKGROUND: Depatuxizumab-mafodotin is an EGFR-directed monoclonal antibody that targets activated EGFR (wild type or EGFRvIII) conjugated to a microtubule inhibitor. EGFRamp correlated with recurrent GBM response in a phase I trial (M12-356, NCT01800695), thus becoming a centrally determined inclus...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Lassman, Andrew, Dimino, Cara, Mansukhani, Mahesh, Murty, Vundavalli, Ansell, Peter J, Bain, Earle, Holen, Kyle D, Roberts-Rapp, Lisa A, Lee, James, Curran, Walter, Mehta, Minesh P, Canoll, Peter
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2017
Teme:
Abstracts
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692946/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.055
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items